•Diverse experiences at emerging biotechnology companies with a recent focus on liver disease and genetic medicines 🧬
•Raised over $1.7 billion and executed multiple licensing/M&A deals (including $877MM sale of Nightstar to Biogen)
•Well-respected by investors, investment bankers, and research analysts (ranked #2 on Institutional Investor All-America Executive Team)
